C suite ey_pharma_3.0_2016
-
Upload
nasri-nahas -
Category
Healthcare
-
view
286 -
download
0
Transcript of C suite ey_pharma_3.0_2016
Pharma 3.0C-Suite series, March 22nd 2016
Frank KumliEmail: [email protected]: @frankkumli
Digital medicine's march on chronic disease Nature Biotechnology 34, 239–246 (2016) http://www.nature.com/
http://www.apple.com/pr/library/2016/03/21Apple-Advances-Health-Apps-with-CareKit.html
http://www.alivecor.com//
http://www.nemauramedical.com/
https://www.veritasgenetics.com/
http://mobihealthnews.com/content/novartis-signs-aetna-cigna-pay-performance-drug-deal-no-remote-monitoring-yet
Page 8
Health outcomesHealth outcomes as currency for health care systems
Value mining► Value-based P&R► Comparative
effectiveness► Risk-sharing
agreements
Consumerism► Health literacy► Empowerment
Health IT► Digital data► Social data► Mobile health
Health care reform► Access► Rebates/discounts► Value-based approach► Health IT
Healthoutcomes
Page 9
Business model transformationFrom products to outcomes
Driversofchange
BusinessModelsValueproposition
Customer
► R&Dproductivity
► Patent cliff► Globalization► Demographics► Pricing & reim-
bursement
► Health carereform
► Health IT► Consumerism► Value mining
BlockbusterDrugs
DiversifiedDrugs Portfolio
HealthOutcomesPharma
1.0
PhysicianPaye
rPatie
nt
Pharma2.0
Pharma 3.0
Page 10
Patient centricityInnovate the industry model around the patient
Page 11
Example 1: Pfizer
Optimizing adherence§ SMS reminder service for
patients on Lipitor, guiding themto a partner pharmacy in theirneighborhood
§ Providers offer the service topatients & collect their consent
§ Patients are directed to«Partner Pharmacies» in theirneighborhood
§ Telecom provider sendsreminder SMS towards the endof each cycle
Page 12
Example 2: J&J JHI
Building non-corecapabilities
• Business-unit dedicated tohealth services
• Top-down strategic decision tofoster collaborative approachesto Healthcare delivery
• Desicated unit dedicated toinnovation and not to corporatesocial responsibility
• First Life Sciences moveradvantage
Page 13
Example 3: Kaiser-Permanente
Optimizing Outcomes§ Integrated payor & provider§ Very high electronic data
transparency for allstakeholders
§ Complete «healthmanagement» for patients
§ Targeted investments inprevention, e.g. standardprophylactic bone marrow scansfor post-menopausal women
§ Collaborations with pharmacompanies in clinical andmedical studies
Page 14
New Business ModelsFive success factors
Page 15
Connect with usDownload our reports at ey.com/VitalSigns
Firepower fireworksDrivers ofbiopharma M&A
Beyond borders2015Global biotech reportReaching new heights
Pulse of the industry2015Medical technology report
How fit is your capitalallocation strategy?Voyage to value
Dr. Frank KumliEY Life Sciences
Ernst & Young
Assurance | Tax | Transactions | Advisory
About Ernst & YoungErnst & Young is a global leader in assurance, tax,transaction and advisory services. Worldwide, our 167,000people are united by our shared values and an unwaveringcommitment to quality. We make a difference by helpingour people, our clients and our wider communities achievetheir potential.
Ernst & Young refers to the global organization of memberfirms of Ernst & Young Global Limited, each of which is aseparate legal entity. Ernst & Young Global Limited, a UKcompany limited by guarantee, does not provide servicesto clients. For more information about our organization,please visit www.ey.com.
Ernst & Young LLP is a client-serving member firm ofErnst & Young Global Limited operating in the US.
© 2016 Ernst & Young LLP.All Rights Reserved.
1303-1040958 _West